CasNo.883558-32-5,Palmitoyl Dipeptide-5 Diaminobutyloyl Hydroxythreonine,(883558-32-5) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: HPLC≥99％
Payment Terms : T/T

Keywords

SkinFirm Dipeptide Palmitoyllysylvalyldiaminobutyroylthreonine Trifluoroacetate Palmitoyl dipeptide-5 diaminobutyroyl threonine trifluoroacetate

Quick Details

Appearance:
Application:Pharmaceuticals;cosmetic;health-care product
PackAge:
ProductionCapacity:|Metric Ton|Day
Storage:2-8℃
Transportation:

Superiority:

We can provide quality files if you need, please contact us for the details.

Besides, you can find more products information through our website: #

Readline

A comprehensive provider of one-stop services for the peptide industry chain,we provide you professional technologies, products and services in the field of peptides.

Professional technology:

liquid phase synthesis technology, solid phase synthesis technology, enzyme catalytic technology, immobilized enzyme catalytic technology, fermentation technology

Professional products:

raw materials (protecting amino acids and derivatives, synthetic resins, purification media and chromatography columns)

intermediates (cosmetic peptides, peptide fragments, custom impurities)

API (peptides, small molecules)

medical devices and equipment (self-injection Pen,all kinds of equipment suitable for peptide development and production)

Professional services:

industry and product consulting, project management, financial and legal risk management, product local registration, quality management and auditing, etc.

Details:

major product:

protected amino acids,

ghk,

glutathione,

injection pen,

adsorption and separation materials,

peptide,

synthetic purification equipment

corporate overview:

Readline was established in 2013. the company is headquartered in the "national science and technology business incubator" in shenzhen nanshan hi-tech industrial park. it is an innovative group company integrating r&d, production, sales, and investment. there are three subsidiaries in the group company: shenzhen redline biotechnology co., ltd. which focuses on the applications of immobilized enzymes technology, shenzhen redline technology co., ltd. which concentrate on "one-stop service for peptide industry chain", and shenzhen redline venture capital partnership (limited partnership)which focuses on venture capital in the medical and health field.

Shenzhen Redline technology co., ltd. was established in 2013. the company focuses on the export of high-quality peptide products from chinese peptide industrial chain, and one-stop service for peptide industry chain. the company's products include: peptide apis, custom synthesized polypeptides, protected amino acids, synthetic resins, coupling reagents, chromatography media, chromatographic packings and columns, chromatographic solvents, peptide devices (synthesis, pyrolysis, purification, nanofiltration, rotary evaporator, lyophilizer , etc.), medical devices (injection pens), polypeptide preparations (injections, implants, patch tablets, etc.), etc.; the company also undertakes the marketization business of internationally innovative medical devices, drugs, and medical services in china. the company provides consulting services on domestic laws and regulations for related products and services, product access contractors, partner recommendations, and signing of related equity documents.

Founded in 2017, Shenzhen Redline biotechnology co., ltd. is an innovative high-tech enterprise led by two postdoctoral fellows in the united states, two leading talents in shenzhen, three university professors, and several listed corporate executives. the company is committed to the applications of immobilized enzymes technology to the development of products such as polypeptides, polysaccharides, and non-natural amino acids. the products developed are widely used in medicine, health products, cosmetics, food, feed, and other industries. the company adopts multidisciplinary technologies of chemistry, materials science and life sciences, which greatly reduces the dependence on the traditional chemical industry, and the emission of “three wastes”, and realizes the green production while improving product quality and economic benefits.

shenzhen redline venture capital partnership (limited partnership) was established in 2017. the company focuses on the investment in entrepreneurial healthcare projects. the company is composed of two leading talents in shenzhen, a world top 500 corporate finance expert, and a director of a charitable foundation. the company is now intensively engaged in the integration and the achievement of the competitive advantage of chinese polypeptide industrial chain in the world. the companies currently investing include chengdu zhengyuan biochemical technology co., ltd., shenzhen redline biotechnology co., ltd., and two new polypeptide drug r&d companies.